Compare RGT & OKYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RGT | OKYO |
|---|---|---|
| Founded | 1986 | 2007 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.4M | 78.2M |
| IPO Year | N/A | 2021 |
| Metric | RGT | OKYO |
|---|---|---|
| Price | $14.16 | $1.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 15.3K | ★ 282.3K |
| Earning Date | 01-01-0001 | 07-20-2026 |
| Dividend Yield | ★ 1.43% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.92 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.58 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.19 | $1.00 |
| 52 Week High | $15.79 | $3.20 |
| Indicator | RGT | OKYO |
|---|---|---|
| Relative Strength Index (RSI) | 39.44 | 33.79 |
| Support Level | $14.04 | N/A |
| Resistance Level | $14.80 | $1.70 |
| Average True Range (ATR) | 0.30 | 0.13 |
| MACD | -0.08 | -0.03 |
| Stochastic Oscillator | 0.00 | 20.23 |
Royce Global Value Trust Inc is a diversified closed-end investment company. The Fund spreads its investments across diversified sectors such as information technology, consumer discretionary, health care, materials, consumer staples and energy. Geographically, it has presence in the United Kingdom, Japan, the United States, Canada, France, Hong Kong and Germany.
OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.